AzTrials
AzTrials

Vital Pulp TherapiesNCT06871709

Clinical and Radiographic Evaluation of Potassium Nitrate in Polycarboxylate Versus Mineral Trioxide Aggregate in Vital Pulpotomy in Primary Molars

A study testing Potassium Nitrate in Polycarboxylate cement and MTA-Anglus in people with Vital Pulp Therapies and Pulpotomy, run by Cairo University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this RCT is to compare the clinical/radiographic outcomes of Potassium nitrate in polycarboxylate cement and MTA as pulpotomy biomaterials used for asymptomatic vital primary lower second molar and this will help to clinically evaluate the use of alternative material in vital pulpotomy in primary molars… Read more about this study

Who is it for?
Ages 4 to 7 yearsHealthy volunteers can take part
What is being tested?
Potassium Nitrate in Polycarboxylate cement and MTA-Anglus
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteEgypt
Study dates
30 May 2025to 30 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 7 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

None listed.

Who cannot join

  • Children with a physical disability or medical disability.
  • Unrestorable molars.
  • Uncooperative patient.
  • Parent unable to attend Follow- up visits.
  • Parents refuse to give written informed consent.
  • If the access was opened and irreversible pulpitis was evident.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mariam M El-Mosallamy, bachelor's degree in dentistry contact

+201066761063

mariamm.ahmoud@dentistry.cu.edu.eg

Egypt1 site
  • Cairo University

    Cairo

Other trials in Egypt

About this study

Official title: Clinical and Radiographic Evaluation of Potassium Nitrate in Polycarboxylate Versus Mineral Trioxide Aggregate in Vital Pulpotomy in Primary Molars: a Randomized Clinical Trial

The purpose of this RCT is to compare the clinical/radiographic outcomes of Potassium nitrate in polycarboxylate cement and MTA as pulpotomy biomaterials used for asymptomatic vital primary lower second molar and this will help to clinically evaluate the use of alternative material in vital pulpotomy in primary molars with deep carious cavities.

Emphasis is set on avoiding total pupectomy and maintaining radicular pulp vitality therefore maintain the tooth in a viable condition till it's shedding and eruption of the permanent successor.

Read the detailed description

Introduction:

Dental caries continues to be a significant health issue, with a very high prevalence in children worldwide. For a variety of reasons (lack of proper dental education, lack of access to dental care, "silent symptomatology," etc.), treatment is frequently initiated once the progression degree has reached a deep, cavitated stage, often with pulp involvement. The primary purpose of pulp therapy in deciduous dentition is to promote the health of the teeth and their supporting tissues in order to maintain the proper functions of the oro-facial complex (mastication, speech, aesthetics), and ultimately to retain the teeth in their position to preserve arch length. Primary teeth are referred to as "the best space maintainers" as they effectively preserve space for their successors.

Carious primary teeth with normal pulp or reversible pulpitis should be treated with vital pulp procedures. Currently, three vital pulp therapy (VPT) options exist for treating deep dentin caries lesions approximating the pulp in vital primary teeth: indirect pulp treatment (IPT), direct pulp cap (DPC), and pulpotomy.

VPT is primarily recommended to be performed in young patients because of the high healing capacity of pulp tissue compared to older patients. An adequate blood supply is required to maintain the pulp's vitality. Furthermore, the presence of a healthy periodontium is required for VPT to be effective, as teeth with moderate to severe periodontal disease are not candidates for treatment. In cases with an inadequate coronal seal and subsequent bacterial microleakage, the prognosis for VPT is significantly reduced.

Pulpotomy is a conservative clinical procedure performed on pediatric patients, and most recently on adult patients too, that involves the removal of the coronal pulp while preserving the radicular pulp. The rationale is based on the healing capacity of the remaining pulp tissue following surgical amputation of the affected or infected coronal pulp. Following hemostasis, the exposed pulp is covered with either a pulp-capping agent that promotes healing or an agent to fix the underlying tissue.

Most recently, Mineral Trioxide Aggregate (MTA) has been the gold standard material for primary tooth pulpotomy. MTA has antimicrobial properties, excellent sealing ability, is bio-compatible and has a dentinogenic effect on pulp tissue by stimulating the release of cytokines from bone cells, which promotes hard tissue formation. Furthermore, MTA maintains pulp tissue integrity while having no cytotoxic effects. Nevertheless, the clinical application of MTA has been limited due to some properties such as its long setting time, difficulty in its handling, being washed out, discoloration, and increased cost. These urged the search for an alternative pulpotomy material to MTA.

Potassium Nitrate (KNO3) is an effective desensitizer for hypersensitive teeth9. Animal studies found satisfactory results using the combination of 5% KNO3 in polycarboxylate cement as a direct pulp capping material10. Clinical studies examined KNO3 in polycarboxylate as a pulp capping or pulpotomy material in vital pulp therapy.

Indirect capping with 5% KNO3 in polycarboxylate cement was compared to calcium hydroxide liner in treating reversible pulpitis in permanent teeth. The study found that 5% KNO3 in polycarboxylate cement provided effective analgesia and restored electrical excitability faster than calcium hydroxide.

A study showed that after two years of direct capping with KNO3 /dimethyl isosorbide/polycarboxylate cement in carious exposed vital pulp, all patients remained clinically and radiographically normal. Another 4-year clinical and radiographic evaluation of teeth treated with KNO3 in polycarboxylate for deep exposed and non-exposed carious lesions revealed a 97.7% success rate in the exposed group and 100% success rate in the non-exposed group.

Furthermore, on a recently published clinical study that was carried out on young immature lower first permanent molars in the Endodontic department, Faculty of dentistry, Cairo university, that was comparing KNO3 in polycarboxylate to MTA. It was revealed that KNO3 in polycarboxylate cement is a viable and cost-effective alternative to MTA for pulpotomy in immature caries-exposed permanent molars.

In conclusion, KNO3 in polycarboxylate offers low cost and easy manipulation. However, to our knowledge no randomized clinical trials (RCTs) have evaluated the use of polycarboxylate with KNO3 as a pulpotomy material for primary dentition.

Methods:

Study Setting and location

  • Source of patients: this study will be conducted in the outpatient clinics of the Pediatric dentistry and Dental Public Health Department - Faculty of Dentistry, Cairo University - Egypt.
  • Operator: The Principal Investigator.
  • Dental units: Knight Midmark Biltmore dental unit (Midmark Corporation 1700 S. Patterson Blvd. Suite 400 Dayton, Ohio 45409, USA)
  • X-ray film: Intraoral digital periapical Xray.

Intervention:

The principal investigator will carry out all treatment procedures, and the patients will be randomly assigned to any of them.

For both interventions:

  1. Informed consent from participating children's parents.
  2. Baseline records photographs, percussion test, periapical radiograph and personal data collection.
  3. Diagnostic charts with personal, medical and dental history will be filled.
  4. Allocation (concealed by withdrawing a sealed opaque envelope containing Four-folded numbered papers containing the type of dressing material that will be used then writing the patient's name and I.D. on it and will be opened after performing the access cavity).
  5. Clinical examination will be performed to assess the clinical inclusion criteria. (Pulpal and periapical diagnoses are established after clinical examination).
  6. Preoperative and Postoperative photographs will be taken.
  7. The radiographic examination will be performed by taking a periapical x-ray using (parallel technique) to assess the inclusion criteria. The preoperative radiograph will serve as a reference for the follow-up radiographs. Standardization of the technique to avoid any distortion in the vertical dimension and to provide reproducible images using x-ray holding device.
  8. Preoperative and postoperative radiographs will be taken by parallel technique using XCP film holder.
  9. Administration of inferior local anesthesia at the side of the affected tooth.
  10. Application of rubber dam for isolation, then a standardized pulpotomy procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level. Hemostasis will be achieved by the application of a wet cotton pellet. Children will then be allocated into either one of the groups alternatively depending on the pulpotomy medicament used as follows:

Group I (Experimental group) pulpotomy using KNO3 (potassium salt, Technogene Corp., Egypt) in polycarboxylate cement:

  1. After complete hemostasis, 5% potassium nitrate (powder) (premixed KNO3 with zinc oxide powder (zinc oxideTm , jK Dental Vision, Egypt), 5gm to 95gm by weight) which will mixed with the polyacrylic acid (liquid) (poly zinc +, Prevest DentPro, India) in 1:1 P/L ratio will be applied using a composite applicator and gently placed over the pulp stumps then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled with glass ionomer restoration (Micron Superior, Prevest DentPro, India).
  2. Tooth will be restored with a stainless-steel crown (Kids Crowns, Shinhung, South Korea) cemented using glass ionomer cement (Micron Lutting, Prevest DentPro, India).

Group II (Control group) pulpotomy using MTA (Angelus, Londrina, Brazil):

  1. After complete hemostasis. MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration (Micron Superior, Prevest DentPro, India).
  2. Tooth will then be restored with a stainless-steel crown (Kids Crowns, Shinhung, South Korea) cemented using glass ionomer cement (Micron Lutting, Prevest DentPro, India).
Being tested
Potassium Nitrate in Polycarboxylate cement, MTA-Anglus
Keywords
Mineral Trioxide Aggregate, Potassium Nitrate, MTA, Pulpotomy, Vital Pulpotomy, Vital Pulp therapy, Primary Molars, pulp therapy, Pulp disease
Medical subject headings
Dental Pulp Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Potassium Nitrate in Polycarboxylate cementCombination product

    The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality.

    Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity

  • MTA-AnglusOther

    Mineral Trioxide Aggregate (MTA) has been the gold standard material for primary tooth pulpotomy. MTA has antimicrobial properties, excellent sealing ability, is biocompatible and has a dentinogenic effect on pulp tissue by stimulating the release of cytokines from bone cells, which promotes hard tissue formation. Furthermore, MTA maintains pulp tissue integrity while having no cytotoxic effects. Nevertheless, the clinical application of MTA has been limited due to some properties such as its long setting time, difficulty in its handling, being washed out, discoloration, and increased cost. These urged the search for an alternative pulpotomy material to MTA

Study groups in NCT06871709
Study groupRoleWhat they receive
Group 1 (Potassium Nitrate in Polycarboxylate cement)ExperimentalPotassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
Receives: Combination Product: Potassium Nitrate in Polycarboxylate cement
Group 2 (Mineral Trioxide Aggregates "MTA")Active comparatorMineral trioxide aggregate (MTA) has been recommended as the gold standard for vital pulp therapy as it showed a high success rate clinically and radiographically when compared to other materials due to its biocompatibility, antibacterial properties and excellent sealing ability
Receives: Other: MTA-Anglus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical success rate

    1. Post-operative pain: will be recorded by verbal question to patient/ parent.
    2. Soft tissue pathology: will be recorded by visual clinical examination.
    3. Pain to percussion: will be recorded by percussion test (by the back of the dental mirror).
    4. Pathological mobility: will be recorded by mobility test (pressure using the end of two dental mirrors).

    Measured: Baseline, 1 week, 3 month, 6, 9 and 12 months after treatment

Secondary outcomes (1)
  1. Radiographic success rate

    1. Absence of external and internal root resorption: will be recorded by using intraoral digital periapical X Ray.
    2. Absence of any pulp stones: will be recorded by using intraoral digital periapical X Ray.
    3. Absence of any furcation and periapical radiolucency: will be recorded by using intraoral digital periapical X Ray.
    4. Absence of any widening in periodontal ligament space: will be recorded by using intraoral digital periapical X Ray.

    Measured: Baseline, 3 month, 6 and 12 months after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2025
  2. Study start30 May 2025 (estimated)
  3. Primary completion1 Jan 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06871709
Sponsor's protocol ID
Vital Primary Molars Pulpotmy
Status last verified
Mar 2025
First submitted
4 Mar 2025
Last updated
12 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Potassium Nitrate in Polycarboxylate cement and MTA-Anglus in people with Vital Pulp Therapies and Pulpotomy, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mariam M El-Mosallamy, bachelor's degree in dentistry (+201066761063, mariamm.ahmoud@dentistry.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical success rate (time frame: Baseline, 1 week, 3 month, 6, 9 and 12 months after treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in